Ovid Therapeutics (OVID) Change in Acquisitions & Divestments (2018 - 2026)

Ovid Therapeutics has reported Change in Acquisitions & Divestments for 7 years, with the latest figure at $10.0 million in Q1 2026.

• For the quarter ending Q1 2026, Change in Acquisitions & Divestments changed 0.0% year-over-year to $10.0 million; the trailing twelve-month figure through Mar 2026 stood at $42.0 million (down 61.11% YoY), and the FY2025 full-year result was $42.0 million, down 67.19% from the prior year.
• Change in Acquisitions & Divestments for Q1 2026 stood at $10.0 million, up from $5.0 million in the prior quarter.
• The five-year high for Change in Acquisitions & Divestments was $60.0 million in Q4 2022, with the low at $5.0 million in Q4 2025.
• Historically, Change in Acquisitions & Divestments has averaged $26.0 million across 5 years, with a median of $25.0 million in 2023.
• Annual changes were most pronounced in 2024 — Change in Acquisitions & Divestments surged 280.0% — and 2025, when it plunged 86.84%.
• Ovid Therapeutics' Change in Acquisitions & Divestments stood at $60.0 million in 2022, then plunged by 83.33% to $10.0 million in 2023, then surged by 280.0% to $38.0 million in 2024, then sank by 86.84% to $5.0 million in 2025, then surged by 100.0% to $10.0 million in 2026.
• The last three Change in Acquisitions & Divestments figures came in at $10.0 million (Q1 2026), $5.0 million (Q4 2025), and $10.0 million (Q3 2025), per Business Quant data.